Name: Tango Therapeutics, Inc. (TNGX) Financial Statements
Creator: FinSpry

Tango Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Tango Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	42.07	36.53	24.86	37.04	7.66
Cost of Revenue	143.92	115.20	105.91	77.64	49.99
Gross Profit	-101.85	-78.67	24.86	-40.59	-42.34
Operating Expenses
Research & Development	143.92	115.20	105.91	77.64	0.00
Selling, General & Administrative	43.75	35.50	30.03	17.60	9.87
Operating Expenses	43.75	150.70	135.93	17.60	9.87
Operating Income	-145.60	-114.17	-111.07	-58.19	-52.20
Other Income/Expense
Interest Income	7.89	6.62	1.46	0.50	0.11
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	7.61	5.94	1.49	-0.25	0.12
Income
Income Before Tax	-130.09	-101.61	-108.12	-57.94	-51.97
Income Tax Expense	0.21	0.13	0.05	0.29	0.00
Net Income	-130.30	-101.74	-108.18	-58.24	-51.97
Net Income - Continuous Operations	-130.30	-101.74	-108.18	-58.24	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-143.10	-111.76	-109.46	-57.29	-51.48
EBIT	-145.60	-114.17	-111.07	-58.19	-52.20
Depreciation & Amortization	2.50	2.42	1.60	0.90	0.72
Earnings Per Share
Basic EPS	-1.00	-1.00	-1.00	-1.00	-2.00
Diluted EPS	-1.00	-1.00	-1.00	-1.00	-2.00
Basic Shares Outstanding	109.23	94.57	87.82	62.11	31.93
Diluted Shares Outstanding	109.23	94.57	87.82	62.11	31.93